A detailed history of Black Rock Inc. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Black Rock Inc. holds 13,760,970 shares of NBIX stock, worth $1.86 Billion. This represents 0.04% of its overall portfolio holdings.

Number of Shares
13,760,970
Previous 13,647,891 0.83%
Holding current value
$1.86 Billion
Previous $1.8 Billion 5.54%
% of portfolio
0.04%
Previous 0.05%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$130.4 - $143.74 $14.7 Million - $16.3 Million
113,079 Added 0.83%
13,760,970 $1.9 Billion
Q4 2023

Feb 13, 2024

BUY
$106.07 - $132.76 $29.3 Million - $36.7 Million
276,493 Added 2.07%
13,647,891 $1.8 Billion
Q3 2023

Nov 13, 2023

SELL
$94.02 - $117.1 $10.4 Million - $13 Million
-110,744 Reduced 0.82%
13,371,398 $1.5 Billion
Q2 2023

Aug 11, 2023

BUY
$89.53 - $104.87 $1.39 Million - $1.62 Million
15,492 Added 0.12%
13,482,142 $1.27 Billion
Q1 2023

May 12, 2023

BUY
$94.11 - $123.02 $79 Million - $103 Million
838,997 Added 6.64%
13,466,650 $1.36 Billion
Q4 2022

Feb 13, 2023

BUY
$106.72 - $127.06 $62 Million - $73.8 Million
580,508 Added 4.82%
12,627,653 $1.51 Billion
Q3 2022

Nov 14, 2022

BUY
$92.03 - $107.81 $11.7 Million - $13.8 Million
127,555 Added 1.07%
12,047,145 $1.28 Billion
Q2 2022

Aug 12, 2022

BUY
$75.79 - $100.07 $24.6 Million - $32.4 Million
324,173 Added 2.8%
11,919,590 $1.16 Billion
Q1 2022

May 12, 2022

BUY
$72.45 - $94.81 $8.61 Million - $11.3 Million
118,872 Added 1.04%
11,595,417 $1.09 Billion
Q4 2021

Feb 10, 2022

BUY
$79.65 - $106.22 $100 Million - $134 Million
1,258,312 Added 12.31%
11,476,545 $977 Million
Q3 2021

Nov 09, 2021

BUY
$86.18 - $99.03 $6.87 Million - $7.9 Million
79,736 Added 0.79%
10,218,233 $980 Million
Q2 2021

Aug 11, 2021

BUY
$89.43 - $102.27 $907 Million - $1.04 Billion
10,138,497 New
10,138,497 $987 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $13B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.